Dr Krill-Jackson on the Practice-Changing Effect of T-DXd in HER2+ Breast Cancer
October 12th 2023
Elisa Krill-Jackson, MD, highlights the practice-changing effects of fam-trastuzumab deruxtecan-nxki in metastatic, HER2-positive breast cancer, as well as whether there is still a role for trastuzumab emtansine in this setting.